Biovica partners with Commercial Organizations to Bring DiviTum(R) TKa to Dutch and Polish Markets
Biovica, a Swedish biotech company known for its unique DiviTum(R) TKa test that measures cell proliferation, announced its partnership with two commercial organizations. The partnership is expected to introduce DiviTum(R) TKa to the Dutch and Polish markets, thereby widening its market reach, and helping cancer patients access better diagnostic tools.
Partnerships with commercial organizations
Biovica teamed up with two well-known commercial organizations to help introduce its diagnostic tool to more patients. The first partner is Match2Cure, a company that helps to find the most suitable partner for different activities, including business development, investment, licensing, and research collaboration. The second partner is Prodiag, a company with vast experience in distributing diagnostic tools throughout the Netherlands and the Dutch-speaking regions in Belgium.
About DiviTum(R) TKa test
DiviTum(R) TKa test is the first test that measures the activity of the drug target, thymidine kinase 1 (TK1) in serum, and it’s used to monitor the effectiveness of chemotherapy in patients with solid tumors. The test has been approved for use in Europe, and several clinical studies have supported its effectiveness in supplementing traditional diagnostic tools.
Cancer diagnosis in the Netherlands and Poland
Cancer is one of the leading causes of mortality among the Dutch and Polish populations. The Netherlands has an estimated 118,000 cancer cases and 44,000 cancer-related deaths annually, while Poland has 165,000 cancer cases and over 100,000 deaths. The introduction of DiviTum(R) TKa test to these markets will help improve cancer diagnosis and management, leading to better outcomes and an increased quality of life for cancer patients.
Impact of the Partnership
Biovica’s partnership with Match2Cure and Prodiag will help introduce DiviTum(R) TKa to new markets, expanding its reach beyond Sweden and other EU countries where the test is currently available. With an increased market reach, more cancer patients in the Netherlands and Poland are expected to access the test, leading to early detection of tumors and better management of cancer.
Biovica has entered new partnerships with Match2Cure and Prodiag to introduce its DiviTum(R) TKa test to the Dutch and Polish markets. Cancer is a leading cause of mortality in these regions, and the introduction of the test will help improve cancer diagnosis and management, leading to better outcomes and an increased quality of life for cancer patients. The test measures the activity of thymidine kinase 1 (TK1) in serum and is used to monitor the effectiveness of chemotherapy in patients with solid tumors. The partnerships with Match2Cure and Prodiag will expand its reach beyond Sweden and other EU countries and increase the number of cancer patients using the test. #Biovica #DiviTumTKa #cancerdiagnosis #Poland #Netherlands #Match2Cure #Prodiag. #BUSINESS